View All Clinical Trials

Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

No search term entered. 367 results shown below.
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning with Low-dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide

Principal Investigator: Lauri Burroughs, MD

Study Number: 2032.00

Phase: II



Gene Therapy for Fanconi Anemia
Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 2097.00

Phase: I



Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen

Principal Investigator: Lauri Burroughs, MD

Study Number: 2256.00

Phase: II



Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 2368.00

Phase: NA



High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Complete title: A Phase II Trial of High-dose 90Y-Ibritumomab Tiuxetan (anti-CD20) followed by Fludarabine and Low-dose Total Body Irradiation and HLA-matched Allogeneic Hematopoietic Transplantation for Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 2398.00

Phase: II



Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2430.00

Phase: II



Scleroderma Treatment with Autologous Transplant (STAT) Study
Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis

Principal Investigator: George Georges, MD

Study Number: 2533.00

Phase: II



Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies

Principal Investigator: Filippo Milano

Study Number: 2603.00

Phase: II



Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma

Principal Investigator: Sylvia Lee, MD

Study Number: 2643.00

Phase: II



Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)
Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)

Principal Investigator: Bart Scott, MD

Study Number: 2661.00

Phase: II



Abatacept as GVHD Prophylaxis Phase 2
Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Principal Investigator: Leslie Kean

Study Number: 2692.00

Phase: II



Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma

Principal Investigator: Seth Pollack

Study Number: 2705.00

Phase: Pilot



Chronic GVHD Response Measures Validation
Complete title: Chronic GVHD Response Measures Validation

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 2710.00

Phase: NA



Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Principal Investigator: Roland Walter, MD

Study Number: 2734.00

Phase: I/II



F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
Complete title: Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy

Principal Investigator: Hannah Linden, MD

Study Number: 7184

Phase: NA



Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study

Principal Investigator: Heidi Gray, MD

Study Number: 7750

Phase: Pilot



Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 7910

Phase: Pilot



Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Complete title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)

Principal Investigator: Hannah Linden, MD

Study Number: 8093

Phase: II



MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Principal Investigator: Nina Mayr, MD

Study Number: 8118

Phase: NA



Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (ITOMIC)
Complete title: Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Subjects with Triple Negative Breast Cancer

Principal Investigator: Tony Blau, MD

Study Number: 8132

Phase: Pilot



Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder (WebQuit Plus)
Complete title: Web-Delivered Acceptance & Commitment Therapy for Smokers with Bipolar Disorder

Principal Investigator: Jaimee Heffner

Study Number: 8363



Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)
Complete title: Together We STRIDE

Principal Investigator: Linda Ko

Study Number: 8417

Phase: II



Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Complete title: Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Principal Investigator: Lauri Burroughs, MD

Study Number: 8508

Phase: Pilot



A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Principal Investigator: Andrei Shustov, MD

Study Number: 9023

Phase: II



Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
Complete title: RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy followed by Ipilimumab in Metastatic Melanoma

Principal Investigator: Ramesh Rengan

Study Number: 9031

Phase: II



JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study

Principal Investigator: Rachel Salit

Study Number: 9033

Phase: II



Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Complete title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) with Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Principal Investigator: Robert Montgomery, MD

Study Number: 9055

Phase: II



Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Principal Investigator: Ajay Gopal, MD

Study Number: 9111

Phase: I/II



Allo vs. Hypomethylating/Best Supportive Care in MDS
Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Principal Investigator: Bart Scott, MD

Study Number: 9129

Phase: III



Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

Principal Investigator: Nora Disis, MD

Study Number: 9140

Phase: I



TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
Complete title: A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma

Principal Investigator: Seth Pollack

Study Number: 9145

Phase: I



WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Complete title: A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Principal Investigator: Eddie Mendez

Study Number: 9168

Phase: I



Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Complete title: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation

Principal Investigator: K.Scott Baker

Study Number: 9223

Phase: II



Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Complete title: Carfilzomib for Treatment of Chronic Graft-versus-Host Disease

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 9228

Phase: II



Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination with MHC Class I Up-regulation and the Anti-PD-L1 Antibody Avelumab

Principal Investigator: Aude Chapuis, MD

Study Number: 9245

Phase: I/II



Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Complete title: Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy after Autologous Transplant for Treating Multiple Myeloma

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9266

Phase: II



Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
Complete title: Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy

Principal Investigator: Jonathan Wright

Study Number: 9274

Phase: II/III



Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Complete title: A Phase I/II Trial of Concurrent Chemohormonal therapy using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Principal Investigator: Heather Cheng

Study Number: 9279

Phase: I/II



Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Complete title: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Principal Investigator: Heidi Gray, MD

Study Number: 9288

Phase: II/III



Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
Complete title: MK-3475 in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Principal Investigator: Stephen Smith

Study Number: 9291

Phase: II



Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)
Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Principal Investigator: Jing Zeng

Study Number: 9328

Phase: III



Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Complete title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide

Principal Investigator: Ajay Gopal, MD

Study Number: 9340

Phase: Pilot



Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)
Complete title: A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)

Principal Investigator: Michael Schweizer

Study Number: 9342

Phase: II



Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)
Complete title: A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells

Principal Investigator: Aleksandra Petrovic

Study Number: 9356

Phase: Pilot



Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)
Complete title: PALS: Prostate Cancer Active Lifestyle Study

Principal Investigator: Jonathan Wright

Study Number: 9369

Phase: NA



Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Complete title: A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

Principal Investigator: Heather Cheng

Study Number: 9381

Phase: Pilot



Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Complete title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP (RID)

Principal Investigator: Robert Montgomery, MD

Study Number: 9388

Phase: I/II



A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Complete title: A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients with Metastatic Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9389

Phase: I



Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
Complete title: A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Castration-Resistant Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9390

Phase: I



Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors
Complete title: Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors

Principal Investigator: Rachel Ceballos

Study Number: 9425

Phase: NA



JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Complete title: A Phase 1b Study of JCAR014, Autologous T cells Engineered to Express a CD19-specific Chimeric Antigen Receptor, in Combination with Durvalumab (MEDI4736) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Principal Investigator: Cameron Turtle, PhD, MBBS

Study Number: 9457

Phase: I



Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Complete title: A Phase II Study of Anti-PD-1 Antibody (MK-3475; pembrolizumab) for the Treatment of Minimal Residual Disease in Adults with Acute Lymphoblastic Leukemia

Principal Investigator: Ryan Cassaday

Study Number: 9458

Phase: II



Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Complete title: Multicenter Phase II, Double-Blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9464

Phase: II



Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Complete title: A Feasibility Study of 'Early' Allogenic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasm

Principal Investigator: Mary-Elizabeth Percival

Study Number: 9567

Phase: Pilot



Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Complete title: Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Principal Investigator: Ann Woolfrey, MD

Study Number: 9577

Phase: Pilot



Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Complete title: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell (DC)/Myeloma Fusions

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9580

Phase: II



ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Complete title: A Phase 2 Study of ARN-509 in Active Surveillance Patients

Principal Investigator: Michael Schweizer

Study Number: 9582

Phase: II



FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)

Principal Investigator: Jing Zeng

Study Number: 9599

Phase: II



Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
Complete title: A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients with Advanced Stage Non-small Cell Lung Cancer that have Progressed through First Line Platinum Doublet Chemotherapy

Principal Investigator: Rafael Santana-Davila

Study Number: 9602

Phase: I/II



Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
Complete title: A Trial of Pembrolizumab in Combination with Doxorubicin as Treatment for Patients with Advanced Sarcomas

Principal Investigator: Seth Pollack

Study Number: 9624

Phase: I/II



Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC)
Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients with Breast Cancer

Principal Investigator: Nora Disis, MD

Study Number: 9626

Phase: I



Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Complete title: Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma

Principal Investigator: Gabriela Chiorean

Study Number: 9627

Phase: I



A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Complete title: A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-Prostatectomy

Principal Investigator: Michael Schweizer

Study Number: 9628

Phase: II



Cisplatin vs Paclitaxel for Triple Neg
Complete title: A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Principal Investigator: Jennifer Specht, MD

Study Number: 9641

Phase: II



Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Complete title: Functional Liver Imaging with Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study

Principal Investigator: Smith Apisarnthanarax

Study Number: 9646

Phase: Pilot



INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL)
Complete title: The GAP4 Study: INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL – MCRPC): A Multicenter, Randomized, Controlled Phase III Study

Principal Investigator: Jonathan Wright

Study Number: 9665

Phase: III



A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Complete title: A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

Principal Investigator: Marco Mielcarek, MD

Study Number: 9710

Phase: II



Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Complete title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Principal Investigator: Mazyar Shadman

Study Number: 9738

Phase: I/II



Endocrine Response in Women With Invasive Lobular Breast Cancer
Complete title: A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer

Principal Investigator: Hannah Linden, MD

Study Number: 9743

Phase: II



Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Complete title: Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults with Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9759

Phase: II



HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
Complete title: HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Principal Investigator: Anna Wald, MD, MPH

Study Number: 9790

Phase: IV



Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)
Complete title: Open Label, Phase II Study of Anti - Programmed Death – Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination with Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Principal Investigator: Bernardo Goulart

Study Number: 9794

Phase: II



TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
Complete title: TraceIT™ Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cancer

Principal Investigator: Jing Zeng

Study Number: 9798

Phase: Pilot



Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)
Complete title: Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)

Principal Investigator: Kanwaldeep Mallhi

Study Number: 9818

Phase: II



Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Complete title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Principal Investigator: Janice Kim, MD

Study Number: A011202

Phase: III



Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)
Complete title: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Principal Investigator: Rachel Yung

Study Number: A221405

Phase: NA



Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Complete title: ACNS0332, Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Principal Investigator: Doug Hawkins, MD

Study Number: ACNS0332

Phase: III



Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: (see comment for full title)

Principal Investigator: Julie Park, MD

Study Number: ENCIT-01

Phase: I



Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Complete title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Principal Investigator: Heidi Gray, MD

Study Number: GOG 0724/ RTOG 0724

Phase: III



Health Effects After Leukemia Research Study #2 (HEAL-2)

Principal Investigator: Eric Chow, MD

Study Number: HEAL-2

Phase: NA



131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01)
Complete title: NANT 2011-01: STUDY OF SINGLE-AGENT 131I-MIBG, 131I-MIBG WITH VINCRISTINE AND IRINOTECAN, OR 131I-MIBG WITH VORINOSTAT FOR RESITANT/RELAPSED NEUROBLASTOMA

Principal Investigator: Julie Park, MD

Study Number: NANT 2011-01

Phase: II



A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Complete title: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Principal Investigator: Rebecca Gardner, MD

Study Number: PLAT-02

Phase: I/II



A Phase 1 Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia (PLAT-04)
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia

Principal Investigator: Corinne Summers

Study Number: PLAT-04

Phase: I



Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)
Complete title: SC-2006. Interfant 06, International Collaborative Treatment Protocol For Infants Under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia

Principal Investigator: Rebecca Gardner, MD

Study Number: SC-2006

Phase: III



Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)
Complete title: SC-2015, A Feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction in patients with relapsed acute lymphoblastic leukemia (ALL)

Principal Investigator: Todd Cooper

Study Number: SC-2015

Phase: I



Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Complete title: SC-2025, Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Principal Investigator: Todd Cooper

Study Number: SC-2025

Phase: I



Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Complete title: SC-4002, An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Principal Investigator: Navin Pinto, MD

Study Number: SC-4002



ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma
Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6015

Phase: I



A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Complete title: A Pilot Study Evaluating the use of the mTOR Inhibitor Sirolimus in Children and Young Adults with Desmoid-Type Fibromatosis

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6016

Phase: Pilot



Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
Complete title: SC-9002: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paciltaxel, and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoeitic Stem Cell Rescue (AuHSCR) for patients with…

Principal Investigator: Sarah Leary

Study Number: SC-9002

Phase: II



Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Complete title: Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma

Principal Investigator: Sarah Leary

Study Number: SC-9008

Phase: Pilot



Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)
Complete title: PHASE II STUDY OF ALISERTIB AS A SINGLE AGENT IN RECURRENT AND REFRACTORY CENTRAL NERVOUS SYSTEM ATYPICAL TERATOID RHABDOID TUMORS (ATRT) AND EXTRA-CNS MALIGNANT RHABDOID TUMORS (MRT) AND IN COMBINATION THERAPY IN NEWLY DIAGNOSED ATRT (SJATRT)

Principal Investigator: Sarah Leary

Study Number: SC-9010

Phase: II



Construction of a Metastatic Osteosarcoma Tissue Microarray

Principal Investigator: Doug Hawkins, MD

Study Number: SC-B604



Evaluation of microRNAs as novel markers of cardiotoxicity in children undergoing anthracycline therapy for pediatric cancer

Principal Investigator: Kasey Leger, MD

Study Number: SC-B610



Genetic Risk Factors of Ewing Sarcoma

Principal Investigator: Doug Hawkins, MD

Study Number: SC-B611



Exploring Genetic Changes In Pediatric Brain Tumors

Principal Investigator: Sarah Leary

Study Number: SC-B904



Decision-making for the child with relapsed or refractory neuroblastoma

Principal Investigator: Abby Rosenberg

Study Number: SC-N110



Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Complete title: T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

Principal Investigator: Todd Cooper

Study Number: T2012-002

Phase: I



Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Principal Investigator: Ann Dahlberg

Study Number: 2010.00

Phase: II



A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Complete title: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

Principal Investigator: Elizabeth Loggers

Study Number: 20132286

Phase: II



Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2206.00

Phase: II



Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 2241.00

Phase: II



Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases

Principal Investigator: George Georges, MD

Study Number: 2260.00

Phase: II



Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant
Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen

Principal Investigator: Filippo Milano

Study Number: 2275.00

Phase: II



Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Principal Investigator: Rachel Salit

Study Number: 2372.00

Phase: II



A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Principal Investigator: Ann Woolfrey, MD

Study Number: 2531.00

Phase: NA



Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation

Principal Investigator: Marco Mielcarek, MD

Study Number: 2546.00

Phase: II



Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies

Principal Investigator: Rachel Salit

Study Number: 2580.00

Phase: III



Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 2639.00

Phase: I/II



HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Complete title: A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction with Standard Chemotherapy for Treatment of Lymphoma in Patients with HIV Infection

Principal Investigator: Mazyar Shadman

Study Number: 2673.00

Phase: I



Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Principal Investigator: Marie Bleakley, MD

Study Number: 2684.00

Phase: II



Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Principal Investigator: Robert Montgomery, MD

Study Number: 6932

Phase: NA



Cognitive Rehabilitation in Cancer Survivors: A Pilot Study

Principal Investigator: Monique Cherrier, PhD

Study Number: 7279

Phase: NA



Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Complete title: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer

Principal Investigator: George Laramore, MD, PhD

Study Number: 7428

Phase: III



Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Complete title: A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin

Principal Investigator: Ajay Gopal, MD

Study Number: 7808

Phase: NA



Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma
Complete title: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

Principal Investigator: George Laramore, MD, PhD

Study Number: 8078

Phase: III



Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Principal Investigator: Gabriela Chiorean

Study Number: 9078

Phase: I



Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9105

Phase: Pilot



Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 9107

Phase: Pilot



HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)
Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine

Principal Investigator: K.Scott Baker

Study Number: 9213

Phase: II



COcoa Supplement and Multivitamin Outcomes Study (COSMOS)
Complete title: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Trial Protocol

Principal Investigator: Garnet Anderson, PhD

Study Number: 9214

Phase: NA



High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Complete title: Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 9226

Phase: Pilot



Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 9330

Phase: I



huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Complete title: A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-targeted Chimeric Antigen Receptor (CAR)-Modified T cells Bearing a Human Binding Domain, in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia

Principal Investigator: Cameron Turtle, PhD, MBBS

Study Number: 9364

Phase: I



Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Complete title: A Phase II Study of Deferasirox in Patients with Red Blood Cell Transfusion Dependent Myelodysplastic Syndromes

Principal Investigator: Bart Scott, MD

Study Number: 9422

Phase: II



Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children
Complete title: The Enhancing Connections Program in Palliative Care: Taking Care of the Children

Principal Investigator: Frances Lewis, PhD

Study Number: 9480

Phase: Pilot



Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Complete title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

Principal Investigator: Manoj Menon

Study Number: 9493

Phase: I



Filgrastim, Cladribine, Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Complete title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD status: A Phase 1/2 Study

Principal Investigator: Anna Halpern

Study Number: 9510

Phase: I/II



Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Complete title: A Window Study of Ixazomib in Untreated Indolent B-NHL

Principal Investigator: Ajay Gopal, MD

Study Number: 9571

Phase: II



211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Complete title: A Study Evaluating Escalating Doses of 211At-labeled anti-CD45 MAb BC8-B10 (211At-BC8-B10) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Principal Investigator: Brenda Sandmaier, MD

Study Number: 9595

Phase: I/II



Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
Complete title: A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma

Principal Investigator: Robert Montgomery, MD

Study Number: 9618

Phase: I



A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
Complete title: A Phase I/ II Study of chemo radiation plus the Anti-PD-1 Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma

Principal Investigator: Tina Rodriguez, MD

Study Number: 9649

Phase: I/II



Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Complete title: Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care

Principal Investigator: Elizabeth Loggers

Study Number: 9667

Phase: Pilot



Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Complete title: ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy with Concurrent Nelfinavir and Nivolumab in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

Principal Investigator: Ramesh Rengan

Study Number: 9712

Phase: II



Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Complete title: Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Principal Investigator: Sarah Buckley

Study Number: 9713

Phase: I



Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Complete title: A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Principal Investigator: Seth Pollack

Study Number: 9717

Phase: I/II



Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Complete title: A Phase II Randomized, Placebo -Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

Principal Investigator: Joshua Hill

Study Number: 9733

Phase: II



Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Complete title: Anti-PD-1 Therapy in Combination with Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Principal Investigator: John Liao

Study Number: 9740

Phase: I/II



IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
Complete title: A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery

Principal Investigator: John Liao

Study Number: 9760

Phase: II



Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Complete title: A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults with Acute Lymphoblastic Leukemia/Lymphoma

Principal Investigator: Ryan Cassaday

Study Number: 9770

Phase: II



Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Complete title: Management of Acute Venous Thromboembolic Events (VTE) in Patients with Hematologic Disorders and Treatment-Induced Thrombocytopenia: a Pilot Study

Principal Investigator: Bethany Samuelson

Study Number: 9799

Phase: NA



Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Complete title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita/telomere disease

Principal Investigator: Lauri Burroughs, MD

Study Number: 9861

Phase: II



Improving Physical Activity in Young Adult Cancer Survivors (This study is enrolling participants by invitation only)
Complete title: Improving physical activity in young adult cancer survivors

Principal Investigator: K.Scott Baker

Study Number: 9865

Phase: NA



Long Term Follow-Up of Patients Previously Entered on Children's Hospital and Regional Medical Center Hematology/Oncology Clinical Trials

Principal Investigator: K.Scott Baker

Study Number: CHMC-L001



NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Complete title: Molecular Analysis for Therapy Choice (MATCH)

Principal Investigator: Fred Appelbaum, MD

Study Number: EAY131

Phase: II



PD-1 Pathway Protein Expression in Pediatric Cancer

Principal Investigator: Doug Hawkins, MD

Study Number: SC-B609



Prospective Blood Collection for Local Immunotherapy Pre-Clinical Studies

Principal Investigator: Rebecca Gardner, MD

Study Number: SC-B801



Computer Based Tool to Explore Symptom Clusters in Adolescents with Cancer

Principal Investigator: Catherine Macpherson, PhD, RN

Study Number: SC-N104

Phase: NA



Resilience in Serious Illness: a pilot feasibility study of the Promoting Resilience in Stress Management (PRISM) Intervention

Principal Investigator: Abby Rosenberg

Study Number: SC-N108



A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Complete title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer

Principal Investigator: Abby Rosenberg

Study Number: SC-N114

Phase: Pilot



PRISM for Parents of Children With Cancer Promoting Resilience in Stress Management (PRISM) Intervention for Parents of Children With Cancer
Complete title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention in Parents of Children with Cancer

Principal Investigator: Abby Rosenberg

Study Number: SC-N120

Phase: Pilot



Hypospadias, Indescended Testis, and Testicular Tumors: A Data and Specimen Banking Pilot Study

Principal Investigator: Margarett Shnorhavorian

Study Number: SCH-HUT-1



A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Complete title: TACL 2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.

Principal Investigator: Todd Cooper

Study Number: TACL 2014-001

Phase: I



Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Complete title: A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)

Principal Investigator: Paul Nghiem

Study Number: 8269a

Phase: II



A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma
Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-Small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer

Principal Investigator: Sylvia Lee, MD

Study Number: 9103A

Phase: I



S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: 9174

Phase: III



Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Complete title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Principal Investigator: Gabriela Chiorean

Study Number: 9412

Phase: II/III



FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Complete title: [F18] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer

Principal Investigator: Hannah Linden, MD

Study Number: 9594

Phase: II



Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Complete title: Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Principal Investigator: Li-Ming Fang

Study Number: 9701

Phase: III



Breast Cancer WEight Loss Study (BWEL Study)
Complete title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: A011401

Phase: III



Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
Complete title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Principal Investigator: Julie Gralow, MD

Study Number: A011502

Phase: III



Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
Complete title: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Principal Investigator: Andrew Coveler, MD

Study Number: A021501

Phase: II



Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Complete title: A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: A051301

Phase: III



Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Rafael Santana-Davila

Study Number: A081105

Phase: III



Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Complete title: A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma

Principal Investigator: Lee Cranmer

Study Number: A091202

Phase: II



Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator: Rafael Santana-Davila

Study Number: A151216

Phase: NA



Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Complete title: AALL05B1, A Children's Oncology Group Protocol for the Collecting and Banking of Relapsed Acute Lymphoblastic Leukemias

Principal Investigator: Doug Hawkins, MD

Study Number: AALL05B1



Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Complete title: AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).

Principal Investigator: Doug Hawkins, MD

Study Number: AALL08B1



Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Complete title: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).

Principal Investigator: Doug Hawkins, MD

Study Number: AALL0932

Phase: III



Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Complete title: AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

Principal Investigator: Doug Hawkins, MD

Study Number: AALL1131

Phase: III



Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Principal Investigator: Kasey Leger, MD

Study Number: AALL1231

Phase: III



Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Complete title: AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Rebecca Gardner, MD

Study Number: AALL1331

Phase: III



A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Complete title: AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway –Mutant Acute Lymphoblastic Leukmia

Principal Investigator: Colleen Annesley, MD

Study Number: AALL1521

Phase: II



Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Complete title: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Principal Investigator: Todd Cooper

Study Number: AAML1331

Phase: III



Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Complete title: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia

Principal Investigator: Todd Cooper

Study Number: AAML1421

Phase: I/II



Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Complete title: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Principal Investigator: Todd Cooper

Study Number: AAML1531

Phase: III



Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Complete title: ACCL1033, A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Principal Investigator: Eric Chow, MD

Study Number: ACCL1033

Phase: NA



Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Complete title: ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) and Local Data Collection

Principal Investigator: Doug Hawkins, MD

Study Number: ACCRN07



Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Complete title: ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Principal Investigator: Doug Hawkins, MD

Study Number: ACNS0831

Phase: III



Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)

Principal Investigator: Julie Park, MD

Study Number: ADVL1212

Phase: I



WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Complete title: ADVL1312, A PHASE 1/2 STUDY OF MK-1775 (AZD1775, IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

Principal Investigator: Julie Park, MD

Study Number: ADVL1312

Phase: I/II



Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Julie Park, MD

Study Number: ADVL1412

Phase: I/II



Study of Selinexor in Pediatric Solid Tumors
Complete title: ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1414

Phase: I



A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Complete title: ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1416

Phase: I



Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Complete title: AEWS07B1, A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

Principal Investigator: Doug Hawkins, MD

Study Number: AEWS07B1

Phase: NA



Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Complete title: AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Principal Investigator: Doug Hawkins, MD

Study Number: AEWS1221

Phase: II



Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Complete title: AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment

Principal Investigator: Doug Hawkins, MD

Study Number: AHEP0731

Phase: III



Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Complete title: AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Principal Investigator: Doug Hawkins, MD

Study Number: AHOD1331

Phase: III



Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Complete title: ALTE07C1, Neuropyschological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Principal Investigator: Doug Hawkins, MD

Study Number: ALTE07C1

Phase: NA



Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Complete title: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial.

Principal Investigator: Eric Chow, MD

Study Number: ALTE1621

Phase: II



Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Complete title: ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study

Principal Investigator: Julie Park, MD

Study Number: ANBL1232

Phase: III



Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Complete title: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Principal Investigator: Doug Hawkins, MD

Study Number: ARST1321

Phase: II



A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma

Principal Investigator: Doug Hawkins, MD

Study Number: COG ARET0231

Phase: III



Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Complete title: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Principal Investigator: Hannah Linden, MD

Study Number: E2112

Phase: III



Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
Complete title: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

Principal Investigator: Habib Rahbar

Study Number: EA1141

Phase: II



Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)
Complete title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Principal Investigator: Rafael Santana-Davila

Study Number: EA5142

Phase: III



Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
Complete title: COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling

Principal Investigator: Fred Appelbaum, MD

Study Number: EAQ152

Phase: II



Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Complete title: Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?

Principal Investigator: Heidi Gray, MD

Study Number: GOG 0225

Phase: III



Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Complete title: NANT 2011-04: A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma

Principal Investigator: Julie Park, MD

Study Number: NANT 2011-04

Phase: II



N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
Complete title: NANT 2012-01 PHASE I STUDY OF DIFLUOROMETHYLORNITHINE (DFMO) AND CELECOXIB WITH CYCLOPHOSPHAMIDE/TOPOTECAN FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA

Principal Investigator: Julie Park, MD

Study Number: NANT 2012-01

Phase: I



Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (N2013-02)
Complete title: NANT 2013-02: A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients with Relapsed and Refractory Neuroblastoma

Principal Investigator: Julie Park, MD

Study Number: NANT 2013-02

Phase: I



SF1126 for Patients With Relapsed or Refractory Neuroblastoma
Complete title: NANT 2014-01 Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma

Principal Investigator: Julie Park, MD

Study Number: NANT 2014-01

Phase: I



Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Complete title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Principal Investigator: Lia Halasz

Study Number: NRG-BN001

Phase: II



Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
Complete title: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma

Principal Investigator: Smith Apisarnthanarax

Study Number: NRG-GI001

Phase: III



Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Complete title: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Principal Investigator: Stacey Cohen

Study Number: NRG-GI002

Phase: II



Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Principal Investigator: Janice Kim, MD

Study Number: NSABP B-51 / RTOG 1304

Phase: III



Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Complete title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 In Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Principal Investigator: Sarah Leary

Study Number: PBTC-042

Phase: I



PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Complete title: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children

Principal Investigator: Sarah Leary

Study Number: PNOC001

Phase: II



Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E-or BRAF Ins T mutant gliomas

Principal Investigator: Sarah Leary

Study Number: PNOC002

Phase: Pilot



H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
Complete title: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas

Principal Investigator: Sarah Leary

Study Number: PNOC007

Phase: I



Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Complete title: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Principal Investigator: Smith Apisarnthanarax

Study Number: RTOG 1112

Phase: III



Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Complete title: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

Principal Investigator: Ramesh Rengan

Study Number: RTOG 1308

Phase: III



Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Complete title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Principal Investigator: Christina Baik

Study Number: S1400

Phase: II/III



Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
Complete title: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: S1416

Phase: II



Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Complete title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Principal Investigator: Julie Gralow, MD

Study Number: S1418

Phase: III



FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Complete title: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Principal Investigator: Gabriela Chiorean

Study Number: S1513

Phase: II



Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Principal Investigator: Heidi Gray, MD

Study Number: S1609

Phase: II



A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)

Principal Investigator: Ajay Gopal, MD

Study Number: 20110654

Phase: I



Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)

Principal Investigator: William Harris

Study Number: 20111617

Phase: III



Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Principal Investigator: William Harris

Study Number: 20130857

Phase: III



A Safety Study of SGN-LIV1A in Breast Cancer Patients
Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

Principal Investigator: Jennifer Specht, MD

Study Number: 20131069

Phase: I



AZD8186 First Time In Patient Ascending Dose Study
Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186

Principal Investigator: Tia Higano, MD

Study Number: 20131275

Phase: I



Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Complete title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumor

Principal Investigator: Shailender Bhatia, MD

Study Number: 20131294

Phase: I



An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Complete title: An Open-Label, Extension (Rollover) Study Of Vemurafenib in Patients with BRAFV600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.

Principal Investigator: John Thompson, MD

Study Number: 20132215

Phase: III



Safety Study of Anti-LAG-3 in CLL, HL and NHL
Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Principal Investigator: Ajay Gopal, MD

Study Number: 20132238

Phase: I



Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Principal Investigator: Andrei Shustov, MD

Study Number: 20141037

Phase: II



MSB0010718C in Subjects With Merkel Cell Carcinoma
Complete title: A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma

Principal Investigator: Shailender Bhatia, MD

Study Number: 20141039

Phase: II



Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Complete title: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20141655

Phase: I/II



Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
Complete title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Principal Investigator: Edward Libby

Study Number: 20142069

Phase: I



ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Complete title: A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Principal Investigator: Andrei Shustov, MD

Study Number: 20142126

Phase: I/II



ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Complete title: A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies

Principal Investigator: Stephen Smith

Study Number: 20142444

Phase: I/II



A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Complete title: PT2385-101: A Phase 1, Multiple-dose, Dose-escalation Trial of PT2385 Tablets, A HIF-2a Inhibitor, In Patients with Advanced Clear Cell Renal Cell Carcinoma

Principal Investigator: Scott Tykodi, MD

Study Number: 20142479

Phase: I



Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer
Complete title: A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Tia Higano, MD

Study Number: 20142613

Phase: I



A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS

Principal Investigator: John Thompson, MD

Study Number: 20150061

Phase: I



Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20150094

Phase: I



Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

Principal Investigator: Andrew Coveler, MD

Study Number: 20150420

Phase: I



Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Complete title: A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20150436

Phase: I/II



Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Principal Investigator: Gabriela Chiorean

Study Number: 20150466

Phase: I



Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer

Principal Investigator: Renato Martins, MD, MPH

Study Number: 20150645

Phase: I/II



Study of Neukoplast (NK-92) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Complete title: Phase II Study of aNK (activated NK-92, formerly Neukoplast) Infusions in Patients with Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)

Principal Investigator: Shailender Bhatia, MD

Study Number: 20150886

Phase: II



Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Complete title: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20151071

Phase: II



Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Complete title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Principal Investigator: Michi Shinohara

Study Number: 20151086

Phase: III



Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Complete title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Principal Investigator: Robert Montgomery, MD

Study Number: 20151131

Phase: II



A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Complete title: A Randomized Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

Principal Investigator: Lia Halasz

Study Number: 20151231

Phase: II/III



A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Complete title: A Phase I Study to Evaluate The Safety, PHarmacokinetics and PHarmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)

Principal Investigator: Tia Higano, MD

Study Number: 20151318

Phase: I



A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
Complete title: A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Principal Investigator: Lee Cranmer

Study Number: 20151429

Phase: II



A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

Principal Investigator: Laura Chow

Study Number: 20151522

Phase: I



A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]
Complete title: A Phase III, open-label, multicenter, randomized study of mpdl3280a (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with pd-l1-selected, high-risk muscle-invasive bladder cancer after cystectomy

Principal Investigator: Michael Schweizer

Study Number: 20151596

Phase: III



Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Complete title: A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant.

Principal Investigator: Stephen Smith

Study Number: 20151683

Phase: II



A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Complete title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Principal Investigator: William Harris

Study Number: 20151721

Phase: I



A Dose-Finding Study of Folotyn® (Pralatrexate Injection) With Peripheral T-Cell Lymphoma (PTCL)
Complete title: A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) PLUS Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)

Principal Investigator: Andrei Shustov, MD

Study Number: 20151824

Phase: I



Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
Complete title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment

Principal Investigator: Lupe Salazar, MD

Study Number: 20151845

Phase: III



Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)
Complete title: A Phase 1A/1B Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

Principal Investigator: John Thompson, MD

Study Number: 20151981

Phase: I



A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) (CheckMate 374)
Complete title: A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma

Principal Investigator: Scott Tykodi, MD

Study Number: 20152079

Phase: III



A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Complete title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Principal Investigator: John Thompson, MD

Study Number: 20152183

Phase: II



A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Complete title: Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors

Principal Investigator: Shailender Bhatia, MD

Study Number: 20152209

Phase: I/II



A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Complete title: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

Principal Investigator: Lee Cranmer

Study Number: 20152300

Phase: I/II



Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Principal Investigator: Gabriela Chiorean

Study Number: 20152369

Phase: II



Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)
Complete title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Principal Investigator: Heidi Gray, MD

Study Number: 20152389

Phase: I/II



A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Principal Investigator: Andrew Coveler, MD

Study Number: 20152434

Phase: III



A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)
Complete title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation

Principal Investigator: Andrei Shustov, MD

Study Number: 20152441

Phase: I/II



A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Complete title: A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Principal Investigator: Scott Tykodi, MD

Study Number: 20152576

Phase: III



Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)
Complete title: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Principal Investigator: Jennifer Specht, MD

Study Number: 20152617

Phase: II



Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Complete title: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: John Thompson, MD

Study Number: 20152783

Phase: I



A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Complete title: A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma

Principal Investigator: Stephen Smith

Study Number: 20160030

Phase: I



A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20160056

Phase: I



A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
Complete title: monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Principal Investigator: Lupe Salazar, MD

Study Number: 20160464

Phase: II



A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Principal Investigator: Gabriela Chiorean

Study Number: 20160524

Phase: I



Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)
Complete title: BMS CA209-577 (CheckMate 577): A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Principal Investigator: Veena Shankaran

Study Number: 20160534

Phase: III



Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Principal Investigator: Scott Tykodi, MD

Study Number: 20160860

Phase: I/II



Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Complete title: A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Principal Investigator: Tina Rodriguez, MD

Study Number: 20160938

Phase: I/II



A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
Complete title: A Phase 1b, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

Principal Investigator: Stephen Smith

Study Number: 20160991

Phase: I



Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non- Hodgkin’s Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 20161033

Phase: II



A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
Complete title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Principal Investigator: Laura Chow

Study Number: 20161065

Phase: II



Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Principal Investigator: Christina Baik

Study Number: 20161101

Phase: I/II



A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)
Complete title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Principal Investigator: Stacey Cohen

Study Number: 20161165

Phase: III



Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Complete title: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Principal Investigator: Veena Shankaran

Study Number: 20161250

Phase: III



Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Complete title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20161383

Phase: I/II



A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Complete title: A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic nonsmall cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI)

Principal Investigator: Christina Baik

Study Number: 20161388

Phase: I/II



Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Principal Investigator: John Thompson, MD

Study Number: 20161740

Phase: I



Dose-escalation Study of BAY1129980
Complete title: An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Principal Investigator: Rafael Santana-Davila

Study Number: 20161858

Phase: I



Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)
Complete title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Principal Investigator: Cristina Rodriguez

Study Number: 20161878

Phase: II



Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Complete title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)

Principal Investigator: Scott Tykodi, MD

Study Number: 20161907

Phase: II



A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Complete title: I3Y-MC-JPCJ(a) An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator: Gabriela Chiorean

Study Number: 20162123

Phase: II



ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Complete title: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20162178

Phase: III



Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)
Complete title: A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162312

Phase: I/II



A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Complete title: A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Principal Investigator: Tia Higano, MD

Study Number: 20162401

Phase: II



A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)
Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric)

Principal Investigator: Veena Shankaran

Study Number: 20162429

Phase: II



A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Complete title: Phase 1b, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Principal Investigator: Jennifer Specht, MD

Study Number: 20162431

Phase: I



A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Complete title: A phase 1, multicenter, open-label, dose-escalation study of SGN-2FF in patients with advanced solid tumors

Principal Investigator: Laura Chow

Study Number: 20162576

Phase: I



Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Complete title: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Principal Investigator: Andrew Cowan

Study Number: 20162588

Phase: II



Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
Complete title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma

Principal Investigator: Evan Yu, MD

Study Number: 20162614

Phase: III



Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)
Complete title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Principal Investigator: William Harris

Study Number: 20162729

Phase: III



A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
Complete title: A Phase 1/2, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-214 and Anti-PD-L1 (Atezolizumab) or Anti-PD-1 (Nivolumab, Pembrolizumab) in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162818

Phase: I/II



A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Principal Investigator: Scott Tykodi, MD

Study Number: 20162874

Phase: II



A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)
Complete title: Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC

Principal Investigator: Scott Tykodi, MD

Study Number: 20162884

Phase: III



A Trial of TTI-621 for Patients With Hematologic Malignancies
Complete title: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refarctory Hematologic Malignancies

Principal Investigator: Mary-Elizabeth Percival

Study Number: 20162887

Phase: I



Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
Complete title: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20162888

Phase: II



Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)
Complete title: A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy

Principal Investigator: Rafael Santana-Davila

Study Number: 20162925

Phase: III



Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Complete title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Principal Investigator: Evan Yu, MD

Study Number: 20162991

Phase: I/II



A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Complete title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies

Principal Investigator: Ajay Gopal, MD

Study Number: 20170102

Phase: I/II



A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Complete title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Principal Investigator: Stephen Smith

Study Number: 20170154

Phase: III



A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)
Complete title: ATTAIN (15-102-14/ NEKTAR) / A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine

Principal Investigator: Jennifer Specht, MD

Study Number: 20170164

Phase: III



Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Complete title: A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070) IN PATIENTS WITH RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL OR T-CELL NON-HODGKIN LYMPHOMA (NHL)

Principal Investigator: Stephen Smith

Study Number: 20170188

Phase: I/II



A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Complete title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER

Principal Investigator: Christina Baik

Study Number: 20170224

Phase: III



Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Complete title: A PHASE IB, OPEN-LABEL STUDY OF THESAFETY AND TOLERABILITY OF ATEZOLIZUMAB IN COMBINATION WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING TREATMENT WITH AN ANDROGEN PATHWAY INHIBITOR

Principal Investigator: Tia Higano, MD

Study Number: 20170291

Phase: I



Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Complete title: A Phase 1b Clinical Study of CWP232291 in Combination with Cytarabine in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20170427

Phase: I



A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Complete title: A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)

Principal Investigator: Edward Libby

Study Number: 20170585

Phase: III



A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Complete title: A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Principal Investigator: John Thompson, MD

Study Number: 20170681

Phase: I



A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer
Complete title: A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer

Principal Investigator: Andrew Coveler, MD

Study Number: 20170696

Phase: I



An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
Complete title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Principal Investigator: Shailender Bhatia, MD

Study Number: 20170952

Phase: III



Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Complete title: A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer

Principal Investigator: Gabriela Chiorean

Study Number: 20171018

Phase: I/II



ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Complete title: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Principal Investigator: William Harris

Study Number: 20171078

Phase: III



Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Complete title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma

Principal Investigator: Cristina Rodriguez

Study Number: 20171087

Phase: III



A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Complete title: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Principal Investigator: Bethany Murphy

Study Number: 20171232

Phase: II



Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Complete title: A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

Principal Investigator: Hannah Linden, MD

Study Number: 20171553

Phase: I/II



A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Complete title: A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)

Principal Investigator: Terry Gernsheimer, MD

Study Number: 20171575

Phase: I



A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Principal Investigator: Edward Libby

Study Number: 2512.00

Phase: I



Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients
Complete title: A Phase I/II Study of Lintuzumab-Actinium-225 in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 2572.00

Phase: I/II



Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Complete title: A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Principal Investigator: Ann Woolfrey, MD

Study Number: 2615.00

Phase: I/II



ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2653.00

Phase: I



Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)
Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Principal Investigator: William Harris

Study Number: 7627

Phase: III



Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma
Complete title: Feasibility of Assessing Drug Response to Precise Local Injection of Anti-Cancer Drugs Using Presage’s CIVO™ Device in Soft Tissue Sarcoma Patients Undergoing Surgery

Principal Investigator: Seth Pollack

Study Number: 9260

Phase: Pilot



A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (WIRB#20142430)

Principal Investigator: Seth Pollack

Study Number: 9290

Phase: I



Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders

Principal Investigator: Ann Woolfrey, MD

Study Number: 9311

Phase: I/II



Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia (MIPLATE)
Complete title: Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MIPLATE)

Principal Investigator: Sherrill Slichter, MD

Study Number: 9374

Phase: NA



A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9382

Phase: I



A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Complete title: A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes

Principal Investigator: Bart Scott, MD

Study Number: 9414

Phase: I



SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Complete title: A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Principal Investigator: Roland Walter, MD

Study Number: 9498

Phase: I/II



Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
Complete title: A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia or CD25-positive Acute Lymphoblastic Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9513

Phase: I



Trial of CMB305 and Atezolizumab in Patients With Sarcoma (IMDZ-C232)
Complete title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Principal Investigator: Seth Pollack

Study Number: 9521

Phase: II



UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Complete title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction With THERAKOS® CELLEX® Photopheresis Systems in Pediatric Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)

Principal Investigator: Paul Carpenter, MD

Study Number: 9550

Phase: III



Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
Complete title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First Line Therapy in Subjects with Chronic Graft Versus Host Disease

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 9587

Phase: II



A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)
Complete title: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC 122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Principal Investigator: Mazyar Shadman

Study Number: 9597

Phase: I/II



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Elizabeth Loggers

Study Number: 9612

Phase: II



A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Complete title: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 9643

Phase: II



Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)
Complete title: IOMAB-01: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 9645

Phase: III



A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
Complete title: A Phase 1 Study of SGN-CD123A in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Roland Walter, MD

Study Number: 9653

Phase: I



Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Complete title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-Assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Principal Investigator: Joshua Hill

Study Number: 9663

Phase: III



An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Complete title: A Mutli-Center, Open Label, Compassionate Use Extension study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Principal Investigator: Mazyar Shadman

Study Number: 9703

Phase: III



Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Complete title: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Principal Investigator: Bart Scott, MD

Study Number: 9723

Phase: III



Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
Complete title: A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

Principal Investigator: Ann Woolfrey, MD

Study Number: 9726

Phase: III



Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
Complete title: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (Ublituximab) and TGR-1202 in Patients with Relapsed-Refractory CLL or Richter’s Transformation of CLL

Principal Investigator: Mazyar Shadman

Study Number: 9727

Phase: I/II



Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Complete title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory(R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Principal Investigator: David Maloney, MD, PhD

Study Number: 9734

Phase: I



A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Complete title: Phase 1 study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma

Principal Investigator: Damian Green, MD

Study Number: 9736

Phase: I



Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)
Complete title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

Principal Investigator: Mary Flowers, MD

Study Number: 9750

Phase: III



A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Complete title: A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Principal Investigator: Joachim Deeg, MD

Study Number: 9772

Phase: II



Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Complete title: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Principal Investigator: Joachim Deeg, MD

Study Number: 9781

Phase: I



Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)
Complete title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Principal Investigator: Bart Scott, MD

Study Number: 9782

Phase: III



A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Complete title: A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who have Failed to Respond to Steroid Treatment for Acute GVHD

Principal Investigator: Paul Carpenter, MD

Study Number: 9828

Phase: III



A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single-dose Obinutuzumab Pretreatment, in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A, With or Without Single Dose Obinutuzmab Pre-Treatment, in Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Principal Investigator: Mazyar Shadman

Study Number: 9837

Phase: I



Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies

Principal Investigator: Damian Green, MD

Study Number: 9847

Phase: II



Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Complete title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib

Principal Investigator: Bart Scott, MD

Study Number: 9866

Phase: II



A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
Complete title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)

Principal Investigator: David Maloney, MD, PhD

Study Number: 9876

Phase: II



Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Complete title: ADVL1322, A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1322

Phase: II



Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Complete title: SC-2026 Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)

Principal Investigator: Todd Cooper

Study Number: SC-2026

Phase: I



Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Complete title: PANAML: A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Principal Investigator: Todd Cooper

Study Number: SC-2029

Phase: I



A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Complete title: SC-4003, BRF116013, Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors

Principal Investigator: Sarah Leary

Study Number: SC-4003

Phase: I/II



A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Complete title: SC-4005: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Principal Investigator: Erin Pinto

Study Number: SC-4005

Phase: I/II



A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Complete title: SC-4007,EZH-102, A Phase I Study of the EZH2 Inhibitor Tazemtostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Principal Investigator: Erin Pinto

Study Number: SC-4007

Phase: I



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Erin Pinto

Study Number: SC-4008

Phase: II



Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients
Complete title: SC-4011, A Post-Marketing Study to Further Assess the Immunogenicity and Safety of UnituxinTM in High-Risk Neuroblastoma Patients

Principal Investigator: Julie Park, MD

Study Number: SC-4011

Phase: IV



Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors (SCOUT)
Complete title: SC-4012, LOXO-TRK-15003, Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

Principal Investigator: Doug Hawkins, MD

Study Number: SC-4012

Phase: I



Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Complete title: SC-4014 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors

Principal Investigator: Julie Park, MD

Study Number: SC-4014

Phase: I



A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Complete title: A Phase 1, Open-Label, Dose-Escalation Study ofOlaratumab as a Single Agent and in Combination withDoxorubicin, Vincristine/Irinotecan, or High-DoseIfosfamide in Pediatric Patients with Relapsed orRefractory Solid Tumors

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6017

Phase: I



Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Complete title: A Phase I and expanded imaging study of BLZ-100 in pediatric patients with primary central nervous system tumors

Principal Investigator: Sarah Leary

Study Number: SC-9009

Phase: I



Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
Complete title: Phase I-II Study of MEK 162 for Children with Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors

Principal Investigator: Sarah Leary

Study Number: SC-9012

Phase: I/II



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials